Intraperitoneal chemotherapy for ovarian cancer patients: a review of the clinical and cost-effectiveness
Murphy M, Cunningham J
Record ID 32011001249
English
Authors' recommendations:
Chemotherapy regimens that include an IP component improved overall survival and progression-free survival compared to IV chemotherapy in patients with advanced epithelial ovarian cancer. Overall, fewer patients in the IP treatment groups were able to complete all cycles of chemotherapy compared to those in the IV treatment groups. The most common serious adverse events were hematological and gastrointestinal. IP catheter related adverse events included blockage, leakage, infection, diarrhea, bowel perforation, fistula formation, bleeding and pain. IP chemotherapy reduced quality of life compared to IV administration at some time points during treatment but not at one year following therapy.From a societal perspective, IP cisplatin plus IP/IV paclitaxel was more effective and more costly that IV cisplatin/paclitaxel or IV carboplatin/paclitaxel with ICER values exceeding US$50,000.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/L0118_Ovarian_Cancer_final.pdf
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Hyperthermia, Induced
- Injections, Intraperitoneal
- Ovarian Neoplasms
- Peritoneal Neoplasms
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.